Alanine transaminase (ALT) or aspartate transaminase (AST) \< 2 x upper limit of normal (ULN) and total bilirubin \< 1.5 x ULN.
Agrees to not participate in another clinical trial for the treatment of COVID-19 while on study unless the patient's condition has worsened and is considered to be moderate, severe, or critical by the Investigator.
You may not be if
Shortness of breath, hypoxia, or signs of serious lower airway disease.
C-reactive protein, lactate dehydrogenase (LDH), or interleukin-6 (IL-6) \> 1.5 x ULN.
D-dimer or ferritin \> 1.5 x ULN.
Imminently requiring, or currently on, mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
Systolic blood pressure \< 90 mm Hg or diastolic blood pressure \< 60 mm Hg.
Evidence of acute respiratory distress syndrome (ARDS) or systemic inflammatory response syndrome (SIRS)/shock.
Known cardiovascular history, including unstable or deteriorating cardiac disease.
Autoimmune disease.
History of pulmonary embolism (PE), deep vein thrombosis (DVT), or prior clinically significant venous or non-cerebrovascular accident/transient ischemic attack arterial thromboembolic event.
Central nervous system disease or dysfunction.
Requirement for \> 2 anti-hypertensive medications.
Unwilling to refrain from alcohol consumption from Day 1 of admission to the in-patient facility until discharge from the facility.
Adrenal insufficiency.
Clareo Health | A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
